

College of Chemistry and Chemical Engineering, National Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou, P.R. China

Two new compounds from *Ligularia dolichobotrys*

ER-WEI LI, KUN GAO, ZHONG-JIAN JIA

Received October 30, 2003, accepted December 1, 2003

Prof. Zhong-Jian Jia and Kun Gao, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, Gansu 730000, P.R. China
 jiazj@lzu.edu.cn and miaozm@lzu.edu.cn

Pharmazie 59: 646–649 (2004)

Two new compounds, a stigmasterol (**1**) and an eremophilanolide (**2**), were isolated from *Ligularia dolichobotrys* (Diels) together with ten known sesquiterpenoids, two known triterpenes and five known sterols. Their structures were elucidated by spectroscopic methods (IR, MS, ^1H , ^{13}C and 2D NMR). In addition, bakkenolide A (**3**) exhibited effective antitumor activity to human leukemia cells (HL-60), human hepatoma cells (Bel-7402) and human ovarian neoplasm cells (HO-8910).


1. Introduction

The genus *Ligularia* (Compositae) consists of about 150 species, with 100 distributed in China that mostly grow in the Northwestern, Southwestern and Northeastern areas (Hou 1982). Among them, about 27 species have long been used as traditional Chinese medicinal herbs for the treatment of fever and inflammation along with detoxication, invigorating the circulation of blood and soothing pain (Jiangsu College of New Medicine 1977; Chen et al. 1987). No phytochemical investigation of *L. dolichobotrys* has been reported up to now. In this paper, we describe the isolation and structural elucidation of the chemical constituents from the whole plant of this species and the antitumor activity of one of the compounds.


2. Investigations, results and discussion

The air-dried and powdered whole plants of *L. dolichobotrys* were extracted three times at room temperature with petroleum ether (60–90 °C)–Et₂O–MeOH (1 : 1 : 1) (each time for 7 days). The residue was chromatographed on silica gel column with petroleum ether (60–90 °C)–EtOAc gradient in developing ratio. The results of the experiment yielded a new stigmasterol: 3 β ,7 α ,22-trihydroxy-stigmast-5-ene (**1**) and a new eremophilanolide: 8 α -methoxy-6 β -angeloyloxy-eremophil-7(11)-en-8 β ,12-olide-15-oic acid (**2**); ten known sesquiterpenoids: bakkenolide A (**3**) (Paul et al. 1991), 3 β -hydroxy-bakkenolide A (**4**) (Fernando et al. 1989) which was reported as a natural product for the first time and its C-3 epimer 3 α -hydroxy-bakkenolide A (**5**) (Fernando et al. 1989; Harmatha et al. 1976), eremophil-7(11)-en-6 α ,15;8 α ,12-diolide (**6**) (Moriyama et al. 1976), 8 β -methoxy-eremophil-7(11)-en-6 α ,15;8 α ,12-diolide (**7**) (Zhao et al. 1995), eremophil-8(**9**), 7(11)-dien-6 α ,15;8,12-diolide (**8**) (Zhao et al. 1995), liguhodgsonal (**9**) (Bohlmann et al. 1977), aromadendranediol (**10**) (Ammanamanchi et al. 1995), 4 β ,10 α -aromadendranediol-10-methyl-ether (**11**) (Ammanamanchi et al. 1995) and a nor-sesquiterpene annuionone D (**12**) (Francisco et al. 1999);

two known triterpenes friedelin (**13**) (Shashi et al. 1994) and ursolic acid (**14**) (Lee et al. 1993), and five known sterols: 3 β ,5 α ,8 α -trihydroxy-campest-6,22-diene (**15**) (Gao et al. 1997), β -sitosterol (**16**) (Marina et al. 1990), 7-oxositosterol (**17**) (Marina et al. 1990), daucosterol (**18**) (Kuo et al. 1997) and sitoindoside I (**19**) (Luo et al. 2001). Their structures were determined by spectroscopic methods.



Compound **1** was obtained as colorless crystal from acetone. Its EIMS spectrum gave a molecular ion peak at m/z 446 and fragment ion peaks at m/z 428 [$\text{M}-\text{H}_2\text{O}$]⁺, 410 [$\text{M}-2\text{H}_2\text{O}$]⁺ and 395 [$\text{M}-2\text{H}_2\text{O}-\text{Me}$]⁺, corresponding to a

**Table 1:** ^1H NMR, ^{13}C NMR and DEPT data of compound **1**

| H | $\delta_{\text{H}}^{\text{a}}$ | $\delta_{\text{H}}^{\text{b}}$ | C | $\delta_{\text{C}}^{\text{a}}$ | $\delta_{\text{C}}^{\text{b}}$ | DEPT |
|------------|--------------------------------|----------------------------------|----|--------------------------------|--------------------------------|---------------|
| | | | 1 | 37.00 | 38.47 | CH_2 |
| | | | 2 | 31.35 | 32.46 | CH_2 |
| 3 | 3.59 (m) | 3.76 (m) | 3 | 71.30 | 71.01 | CH |
| 4 α | | 2.66 (s) | 4 | 41.99 | 43.71 | CH_2 |
| 4 β | | 2.64 (d, $j = 4.44$ Hz) | | | | |
| | | | 5 | 146.34 | 145.00 | C |
| 6 | 5.61 (d, $J = 4.92$ Hz) | 5.87 (d, $J = 5.13$ z) | 6 | 123.79 | 125.42 | CH |
| 7 | 3.86 (m) | 4.08 (dd, $J = 4.28, 4.35$ Hz) | 7 | 65.31 | 64.79 | CH |
| | | | 8 | 37.39 | 37.57 | CH |
| | | | 9 | 42.27 | 42.75 | CH |
| | | | 10 | 37.39 | 37.77 | C |
| | | | 11 | 20.69 | 21.22 | CH_2 |
| | | | 12 | 39.16 | 39.88 | CH_2 |
| | | | 13 | 42.48 | 42.75 | C |
| | | | 14 | 49.08 | 49.81 | CH |
| | | | 15 | 24.39 | 24.90 | CH_2 |
| | | | 16 | 27.49 | 28.12 | CH_2 |
| | | | 17 | 52.80 | 53.67 | CH |
| 18 | 0.72 (s) | 1.05 (s) | 18 | 11.62 | 11.99 | CH_3 |
| 19 | 1.00 (s) | 0.76 (s) | 19 | 18.22 | 18.48 | CH_3 |
| | | | 20 | 41.38 | 43.38 | CH |
| 21 | 0.79 (d, $J = 6.68$ Hz) | 1.25 (d, $J = 6.83$ Hz) | 21 | 12.28 | 13.09 | CH_3 |
| 22 | 3.74 (brd, $J = 10.3$ Hz) | 4.03 (brdd, $J = 10.2, 2.02$ Hz) | 22 | 71.26 | 70.25 | CH |
| | | | 23 | 29.87 | 30.31 | CH_2 |
| | | | 24 | 42.48 | 41.70 | CH |
| | | | 25 | 28.73 | 29.40 | CH |
| 26 | 0.94 (d, $J = 6.64$ Hz) | 0.98 (d, $J = 6.80$ Hz) | 26 | 20.53 | 20.78 | CH_3 |
| 27 | 0.90 (d, $J = 6.64$ Hz) | 0.87 (d, $J = 6.84$ Hz) | 27 | 17.53 | 18.17 | CH_3 |
| | | | 28 | 23.58 | 23.90 | CH_2 |
| 29 | 0.89 (t, $J = 7.04$ Hz) | 0.90 (t, $J = 7.39$ Hz) | 29 | 11.88 | 12.17 | CH_3 |

^1H NMR (400 MHz), ^{13}C NMR (100 MHz), TMS, δ/ppm
^a measured in CDCl_3 , ^b measured in pyridine- d_5

molecular formula $\text{C}_{29}\text{H}_{50}\text{O}_3$, which was supported by HRESIMS at m/z 429.3742 $[\text{M}-\text{H}_2\text{O}+\text{H}]^+$ (calcd. 429.3757) and 411.3618 $[\text{M}-2\text{H}_2\text{O}+\text{H}]^+$ (calcd. 411.3621). The IR spectrum revealed absorption bonds for $-\text{OH}$ at 3400 cm^{-1} and $\text{C}=\text{C}$ at 1665 cm^{-1} . The ^1H NMR,

^{13}C NMR and DEPT spectra of **1** (Table 1) exhibited signals for $6 \times \text{CH}_3$, $9 \times \text{CH}_2$, $11 \times \text{CH}$, $3 \times \text{C}$, which indicated that the structure of **1** was similar to a stigmasterane skeleton with one double bond and three hydroxyl groups. Compared with the related compound 7α -hydroxystosterol

Table 2: ^1H NMR, ^{13}C NMR and DEPT data of **2**

| H | δ_{H}^* | C | δ_{C}^* | DEPT |
|------------|-------------------------------|-----|-----------------------|---------------|
| | | 1 | 20.9 | CH_2 |
| | | 2 | 24.5 | CH_2 |
| | | 3 | 27.8 | CH_2 |
| 4 α | 2.46 (dd, $J = 12.8, 4.2$ Hz) | 4 | 44.6 | CH |
| | | 5 | 42.7 | C |
| 6 | 5.90 (q, $J = 1.2$ Hz) | 6 | 70.3 | CH |
| | | 7 | 154.2 | C |
| | | 8 | 106.8 | C |
| | | 9 | 38.4 | CH_2 |
| 10 β | 2.85 (m) | 10 | 36.0 | CH |
| | | 11 | 126.3 | C |
| | | 12 | 170.9 | C |
| 13 | 1.84 (d, $J = 1.2$ Hz) | 13 | 8.1 | CH_3 |
| 14 | 1.09 (s) | 14 | 16.1 | CH_3 |
| | | 15 | 178.6 | C |
| OMe | 3.29 (s) | OMe | 50.5 | CH_3 |

^1H NMR (400 MHz), ^{13}C NMR (100 MHz), CDCl_3 , TMS, δ/ppm

* OAng: δ_{H} 6.33 (H_3 , qq, $J = 7.2, 1.4$ Hz), 2.10 (H_4 , dq, $J = 7.2, 1.3$ Hz), 2.01 (H_5 , dq, $J = 1.4, 1.3$)
 δ_{C} 166.5 (C_{17} , s), 126.7 (C_2 , s), 142.2 (C_3 , d), 20.6 (C_4 , q), 19.1 (C_5 , q)

(Marina et al. 1990), the side-chains of both were a little different. Compound **1** had a hydroxyl at C-22 ($\delta_{\text{C}-22}$ 71.26, $\delta_{\text{H}-22}$ 3.74 in CDCl_3) which can be confirmed by the cross signals between δ_{H} 1.25 (H-21) and δ_{C} 70.25 (C-22), δ_{C} 43.38 (C-20), δ_{C} 53.67 (C-17) in the HMBC spectrum (in pyridine- d_5). The configuration of the C-22 can't be determined only by comparing with the spectral data of similar compounds, although the absolute configurations of similar compounds were 22S (Satoshi et al. 1992). Thus compound **1** was deduced as 3 $\beta,7\alpha,22$ -trihydroxy-stigmast-5-ene.

It needs to be said that the NMR spectra of **1** were firstly measured in CDCl_3 , then in pyridine- d_5 in order to compare the results with literature data (Marina et al. 1990) (in CDCl_3) and the literature (Satoshi et al. 1992) (in pyridine- d_5).

Compound **2**, colorless gum, HRESIMS showed $[\text{M} + \text{NH}_4]^+$ at m/z 410.2164 (calcd. 410.2173), and EI-MS showed a molecular ion peak at m/z 392 in accordance with the molecular formula $\text{C}_{21}\text{H}_{28}\text{O}_7$ and the presence of 21 carbons was confirmed by its ^{13}C NMR and DEPT spectral data (Table 2). Its IR bands (1643, 1701, 1769 cm^{-1}) and UV absorption (225 nm) displayed a typical α,β -unsaturated γ -lactone. In the ^1H NMR spectral data, there was an angeloyloxy group and a methoxyl group signals. Except for the -OAng and the - OCH_3 , the ^{13}C NMR and DEPT spectra showed 15 signal for $2 \times \text{CH}_3$ (one of which was tertiary methyl), $4 \times \text{CH}_2$, $3 \times \text{CH}$ (one of which was oxygenated) and $6 \times \text{C}$. Furthermore the signals of C-7 (δ 154.2, s), C-8 (δ 106.8, s), C-11 (δ 126.3, s), C-12 (δ 170.9, s) and C-13 (δ 8.1, q) showed the compound **2** was an eremophilane derivative with an α,β -unsaturated γ -lactone, a COOH-15 group (δ 178.6, s, C-15) (Zhao et al. 1995), a -OAng and a - OCH_3 . The -OAng should be located at C-6 ($\delta_{\text{C}-6}$ 70.3, d), for $\delta_{\text{C}-6}$ must be about 80 ppm if the - OCH_3 was located at C-6 (Li et al. 2002; Mao et al. 2001; Zhang et al. 1998), thus the - OCH_3 located at C-8. Stereochemically, Me-14 and Me-15 are biogenetically β -orientations (Moriyama et al. 1976), so COOH-15 group should be in β -orientation. Besides, the presence of a homoallylic spin-coupling ($J = 1.2$ Hz) between H-6 and H-13 showed that the -OAng at C-6 was in β -orientation and the - OCH_3 at C-8 was in α -orientation (Moriyama et al. 1976; Naya et al. 1975). Therefore, the structure of compound **2** was determined as 8 α -methoxy-6 β -angeloyloxy-eremophil-7(11)-en-8 $\beta,12$ -olide-15-oic

Table 3: IC_{50} ($\mu\text{g}/\text{ml}$) of compound **3**

| Compound | HL-60 | Bel-7402 | HO-8910 |
|-------------|----------------|----------------|----------------|
| Vincristine | 9.6 ± 0.98 | 25.9 ± 3.4 | 20.7 ± 1.9 |
| 3 | 25.5 ± 2.4 | 38.1 ± 4.1 | 56.7 ± 5.1 |

acid. Compound **3** exhibited strong activity against human leukemia cells (HL-60), human hepatoma cells (Bel-7402) and human ovarian neoplasm cells (HO-8910) (Table 3).

3. Experimental

3.1. Equipment

All optical rotations were measured on Perkin-Elmer M341 polarimeter. IR spectra were scanned on a Nicolet 170SX FT-IR spectrometer. ^1H NMR (400 MHz), ^{13}C NMR (100 MHz) spectra and 2D NMR spectra were recorded on a Bruker AM 400FT-NMR spectrometer with TMS as internal reference. HRESI-MS and EI-MS were obtained on Bruker Daltonics APEX II 47e and HP-5988 AGCMS spectrometers respectively. Silica gel (200–300 mesh) was used for CC and silica GF₂₅₄ for TLC. Spots were detected on TLC under UV light or by heating after spraying with 5% H_2SO_4 in $\text{C}_2\text{H}_5\text{OH}$.

3.2. Plant material

The whole plant was collected in August 2000, in Qinling Mountain, Shaanxi Province, People's Republic of China, and was identified by Prof. Y. J. Zhang, Department of Biology, Lanzhou University. A voucher specimen (No. 20000802) was deposited in College of Chemistry and Chemical Engineering, Lanzhou University.

3.3. Extraction and isolation

The air-dried and powdered whole plants (1.0 kg) of *L. dolichobotrys* were extracted three times at room temperature with petroleum ether (60–90 °C)- Et_2O -MeOH (1 : 1 : 1) (each time for 7 days). The resultant extract was concentrated under reduced pressure to a residue (52 g), which was chromatographed on silica gel column with petroleum ether (60–90 °C)- EtOAc in developing gradient yielding ten crude fractions (Fr. 1–Fr. 10). The mixture of compounds **3** and **13** were deposited from Fr. 1 (petroleum ether- EtOAc 50 : 1) and after recrystallized in acetone, **3** (100 mg) and **13** (30 mg) were obtained. From Fr. 4 (petroleum ether- EtOAc 15 : 1), crude **16** was deposited and recrystallized in acetone, gave **16** (30 mg); **9** (17 mg) was purified by preparative TLC (petroleum ether-acetone 4 : 1); **15** (4 mg) was obtained by repeated silica gel column chromatography with petroleum ether- EtOAc (8 : 1). Fr. 5 (petroleum ether- EtOAc 10 : 1) was rechromatographed (petroleum ether- EtOAc 15 : 1) on silica gel column to give compounds **2** (5 mg), **7** (46 mg), **8** (38 mg), **11** (3 mg) and **14** (3 mg). Fr. 7 (petroleum ether- EtOAc 5 : 1) was separated by CC on silica gel with petroleum ether-acetone (10 : 1), crude compounds **5**, **6**, **17** were obtained and

then **6** was further purified by preparative TLC (petroleum ether-acetone 3:2) to afford **6** (34 mg); crude **5** and **17** were further chromatographed on silica gel column with petroleum ether-acetone (6:1) and gave **5** (8 mg) and **17** (6 mg). Fr. 8 (petroleum ether-EtOAc 3:1) was separated by CC on silica gel with petroleum ether-acetone (4:1) and then by preparative TLC (CHCl₃-acetone 5:1) to yield **4** (8 mg), **12** (2 mg) and **10** (3 mg). Compound **1** (11 mg) was afforded from Fr. 9 (petroleum ether-EtOAc 2:1) by CC on silica gel with CHCl₃-acetone (5:1) several times. Compound **18** (30 mg) was deposited and recrystallized in MeOH from Fr. 10 (petroleum ether-EtOAc 1:1). By CC on silica gel with CHCl₃-MeOH (10:1) and then preparative TLC (CHCl₃-MeOH 3:1), compound **19** (20 mg) was also afforded from Fr. 10.

3.4. 3β,7α,22-trihydroxy-stigmast-5-ene (1)

Colorless needle crystals (acetone); m.p. 122–123°C; [α]_D²³ –54° (c. 1.1, CHCl₃); IR (ν^{KBr}, cm⁻¹): 3400, 1665; EIMS m/z (rel int): 446 [M]⁺ (2.2), 428 [M–H₂O]⁺ (81), 410 [M–2H₂O]⁺ (7.9), 300 (47.2), 176 (32.3), 158 (62.7), 105 (55.4), 91 (58.9), 81 (70.4), 69 (91.5), 55 (81.4), 43 (100); ¹H NMR, ¹³C NMR and DEPT data (Table 1).

3.5. 8α-Methoxy-6β-angeloyloxy-eremophil-7(11)-en-8β,12-olide-15-oic acid (2)

Colorless needle crystals (acetone); m.p. 250–251°C; [α]_D²³ –86° (c. 0.5, CHCl₃); IR (ν^{KBr}, cm⁻¹): 3427, 1769, 1701, 1643, 1453, 1382, 1147, 1046; EIMS m/z (rel int): 392 [M]⁺ (7), 360 (3), 310 (8), 292 (17), 260 (30), 232 (36), 203 (16), 171 (13), 83 (100); ¹H NMR, ¹³C NMR and DEPT data (Table 2).

3.6. Antitumor assays

The antitumor activities of compounds **3**, **6**, **7** and **8** were measured in the Department of Biology of Lanzhou University by the SRB (Sulforhodamine B) method (Skehan et al. 1990). Only compound **3** exhibited strong antitumor activity to human leukemia cells (HL-60), human hepatoma cells (Bel-7402) and human ovarian neoplasm cells (HO-8910) (Table 3).

Acknowledgements: This work was financed by National Natural Science Foundation of China (No. 29972017 and No. 20021001-QT Program).

References

Ammanamanchi SRA, Kadali SS, Mukku JRVV (1995) Terpenoid and steroid constituents of the India Ocean soft coral *Sinularia maxima*. Tetrahedron 51: 10997–11010.
Bohlmann F, Ehlers D, Zdero C et al. (1977) Über Inhaltsstoffe der Gattung *Ligularia*. Chem Ber 110: 2640–2648.
Chen LS, Song WZ (1987) General conditions on medicinal plants of *Compositae* in China. ZhongCaoYao (in Chinese) 18: 421–429.

Coelho F, Depres IP, Brocksom TJ, Greene AE (1989) Direct approach to the bakkanes: a synthesis of (±)-homogynolide-B. Tetrahedron Lett 30: 565–566.
Gao K, Jia ZJ (1997) Sterol compounds from *Ligularia dentate*. Journal of Lanzhou University (Natural Sciences in Chinese) 33: 77–80.
Harmatha J, Samek Z, Synackova M et al. (1976) Neutral components of the extract from *Homogine alpina* (L.) Cass. Collection Czechoslov Chem Commun 41: 2047–2058.
Hou KZ (1982) A Dictionary of the Families and Genera of Chinese Seed Plants. 2nd ed., Science Press, p. 276.
Jiangsu College of New Medicine (1977) A Dictionary of the Traditional Chinese Medicines. Shanghai Science and Technology Press, p. 7, 154, 549, 1152, 2349, etc.
Kuo YH, Yeh MH (1997) Chemical constituents of heartwood of *Bauhinia purpurea*. J Chin Chem Soc 44: 379–383.
Lee SM, Lai JS, Kuo YH (1993) Constituents of *Clinopodium umbrosum*. J Chin Chem Soc 40: 87–91.
Li XQ, Gao K, Jia ZJ (2002) Two new eremophilolides from *Ligularia sagitta*. Chin Chem Lett 13: 963–964.
Luo XJ, Wu SH, MaYB et al. (2001) Chemical constituents from *Dysoxylum hainanense*. Acta Botanica Yunnanica (in Chinese) 23: 368–372.
Macias FA, Oliva RM, Varela RM et al. (1999) Allelochemicals from sunflower leaves cv. Peredovick. Phytochemistry 52: 613–621.
Mao MJ, Jia ZJ (2001) Two new eremophilane sesquiterpenes from *Cacalia ainsliaeflora*. Chin Chem Lett 12: 601–602.
Marina DG, Pietro M, Lucio P (1990) Stigmasterols from *Typha latifolia*. J Nat Prod 53: 1430–1435.
Moriyama Y, Takahashi T (1976) New sesquiterpene lactones of eremophilane-type from *Ligularia fauriei* (F.) Koidz Bull Chem Soc Japan 49: 3196–3199.
Naya K, Kanazawa R, Sawada M (1975) The photosensitized oxygenation of furanoeremophilanes I. The isomeric hydroperoxides from petasalin and their transformations to lactones. Bull Chem Soc Japan 48: 3220–3225.
Paul A, Abdelhamid B, Georges M et al. (1991) Eremophilolides from *Hertia cheirifolia*. Phytochemistry 30: 2083–2084.
Satoshi K, Yoshihiro M, Yutaka S et al. (1992) New polyhydroxylated cholestane glycosides from the bulbs of *Ornithogalum saundersiae*. Chem Pharm Bull 40: 2469–2472.
Shashi BM, Asish PK (1994) ¹³CNMR spectra of pentacyclic triterpenoids—a compilation and some salient features. Phytochemistry 37: 1517–1575.
Skehan P, Storeng R, Scudiero D et al. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107–1112.
Zhang SM, Zhao GL, Li R et al. (1998) Eremophilane sesquiterpenes from *Cacalia roborowskii*. Phytochemistry 48: 519–524.
Zhao Y, Jia ZJ, Peng HR (1995) Eight new eremophilane derivatives from the roots of *Ligularia przewalskii*. J Nat Prod 58: 1358–1364.